| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |